



News Release

Suven's Income lower by 7.35%; PAT increase by 19.36% for the quarter ended June 2015

HYDERABAD, INDIA (14 Aug' 2015) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS) today announced its un-audited financial results for the quarter ending 30th June 2015. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Aug 2015 at Hyderabad.

Financial Highlights for the 1st Quarter ended June' 2015: (QoQ)

Growth in revenue Rs 1061 Mn vs. Rs 1145 Mn - Down by 7.35%
Growth in PAT Rs 202 Mn vs. Rs 169 Mn - Up by 19.36%
Growth in EBIDTA Rs 301 Mn vs. Rs 265 Mn - Up by 13.52%

In comparison with the same period of last year, the income was lower by 25.63% and PAT was lower by 41.76%.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 159 Mn (15.03% on revenue) for the quarter ended 30th June 2015.

The Board has authorised to create an overseas subsidiary with an initial investment of US\$ 25 Mn for clinical development and commercialisation of Suven pipeline and in-licensed molecules.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;